CROTTI, LIA
 Distribuzione geografica
Continente #
NA - Nord America 5.098
AS - Asia 4.213
EU - Europa 3.326
SA - Sud America 510
AF - Africa 150
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 9
Totale 13.338
Nazione #
US - Stati Uniti d'America 4.952
CN - Cina 2.121
SG - Singapore 909
IE - Irlanda 799
HK - Hong Kong 447
UA - Ucraina 388
IT - Italia 382
RU - Federazione Russa 369
DE - Germania 368
VN - Vietnam 359
BR - Brasile 356
FI - Finlandia 353
FR - Francia 208
GB - Regno Unito 179
SE - Svezia 107
CA - Canada 91
IN - India 85
ZA - Sudafrica 79
AR - Argentina 64
BD - Bangladesh 52
IQ - Iraq 41
BE - Belgio 35
MX - Messico 33
JP - Giappone 31
PL - Polonia 25
EC - Ecuador 22
AT - Austria 21
CO - Colombia 21
NL - Olanda 21
AU - Australia 19
PK - Pakistan 19
TR - Turchia 19
PH - Filippine 17
VE - Venezuela 17
MA - Marocco 15
ES - Italia 14
KE - Kenya 12
NZ - Nuova Zelanda 12
UZ - Uzbekistan 12
MY - Malesia 11
TN - Tunisia 11
SA - Arabia Saudita 10
CL - Cile 9
ID - Indonesia 9
JO - Giordania 8
AE - Emirati Arabi Uniti 7
BO - Bolivia 7
DZ - Algeria 7
ET - Etiopia 7
KZ - Kazakistan 7
PE - Perù 7
RO - Romania 7
CH - Svizzera 6
DO - Repubblica Dominicana 6
EG - Egitto 6
EU - Europa 6
IR - Iran 6
AL - Albania 5
AZ - Azerbaigian 5
BG - Bulgaria 5
CZ - Repubblica Ceca 5
DK - Danimarca 5
IL - Israele 5
KG - Kirghizistan 5
KR - Corea 5
NP - Nepal 5
PY - Paraguay 5
CR - Costa Rica 4
GR - Grecia 4
LT - Lituania 4
LU - Lussemburgo 4
NI - Nicaragua 3
OM - Oman 3
PA - Panama 3
PT - Portogallo 3
BB - Barbados 2
HU - Ungheria 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LV - Lettonia 2
LY - Libia 2
NO - Norvegia 2
QA - Qatar 2
TH - Thailandia 2
UY - Uruguay 2
ZW - Zimbabwe 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
CI - Costa d'Avorio 1
CM - Camerun 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GI - Gibilterra 1
GN - Guinea 1
HN - Honduras 1
KH - Cambogia 1
Totale 13.326
Città #
Dublin 796
Chandler 708
Jacksonville 493
Singapore 465
Ashburn 461
Hong Kong 437
Nanjing 436
Beijing 388
San Jose 380
Dallas 370
Boardman 200
Nanchang 171
Wilmington 145
Ho Chi Minh City 141
Princeton 140
Lawrence 138
Shenyang 135
Lauterbourg 129
Los Angeles 123
Changsha 121
Helsinki 120
Hebei 119
Ann Arbor 118
Jiaxing 108
Medford 97
Milan 97
New York 87
Hanoi 83
Johannesburg 72
Hangzhou 71
Pavia 66
Shanghai 66
Tianjin 63
Redondo Beach 61
Moscow 59
Buffalo 57
Munich 49
Toronto 44
São Paulo 40
Woodbridge 36
Frankfurt am Main 32
Tokyo 31
Brussels 29
Seattle 28
Norwalk 27
Houston 25
Nuremberg 24
Orem 24
Falkenstein 23
Verona 23
Fairfield 21
Turku 21
Warsaw 20
Brooklyn 19
London 19
Ottawa 19
Baghdad 18
Zhengzhou 18
Chennai 17
Santa Clara 17
Chicago 16
Denver 16
Des Moines 16
Kunming 16
San Francisco 16
Manchester 15
Falls Church 14
Haiphong 14
The Dalles 14
Atlanta 13
Boston 13
Guangzhou 13
Trieste 13
Bergamo 12
Phoenix 12
Pune 12
Stockholm 12
Amsterdam 11
Florence 11
Jinan 11
Montreal 11
Nairobi 11
Tashkent 11
Columbus 10
Belo Horizonte 9
Da Nang 9
Dhaka 9
Hải Dương 9
Mexico City 9
Piscataway 9
Poplar 9
Quito 9
Amman 8
Berlin 8
Buenos Aires 8
Council Bluffs 8
Mumbai 8
Rochester 8
Secaucus 8
Addis Ababa 7
Totale 8.793
Nome #
Mapping the human genetic architecture of COVID-19 289
A first update on mapping the human genetic architecture of COVID-19 189
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. 148
Long QT and short QT syndromes. 146
A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome. 145
PREDESTINATION: PRimary vEntricular fibrillation and suDden dEath during a firST myocardIal iNfArcTION: Genetic basis. 142
Gene symbol: KCNH2 138
Identification of a KCNQ1 polymorphism acting as a protective modifier against arrhythmic risk in long-QT syndrome. 135
Spectrum and prevalence of mutations involving BrS1-12 susceptibility genes in a cohort of unrelated patients referred for Brugada Syndrome genetic testing: implications for genetic testing. 133
FGF12 is a candidate Brugada syndrome locus. 132
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 132
Multiscale complexity analysis of the cardiac control identifies asymptomatic and symptomatic patients in long QT syndrome type 1. 131
AKAP9 is a genetic modifier of congenuital Long-QT Syndrome type 1 125
Long QT syndrome-associated mutations in intrauterine fetal death. 121
Novel human pathological mutations. Gene symbol: SCN5A. Disease: Brugada Syndrome. 119
Electrocardiographic and genetic screening for long QT syndrome: results from a prospective study on 44,596 neonates. 116
Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study 116
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 114
Cardiac arrhythmias of genetic origin are important contributors to Sudden Infant Death Syndrome. 113
Inherited cardiac arrhythmia syndrome. Role of potassium channels 113
A novel disease gene for Brugada syndrome: sarcolemmal membrane-associated protein gene mutations impair intracellular trafficking of hNav1.5. 112
Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes 112
A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. 111
The genetics underlying acquired long QT syndrome: impact for genetic screening. 111
All LQT3 patients need an ICD. True or false? 110
Cardiac sodium channel dysfunction in sudden infant death syndrome. 110
Arrhythmogenic disorders of genetic origin. Long QT Syndrome: from genetics to management. 110
Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3′ Untranslated Region of KCNQ1? 110
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene 110
The LQT2 KCNH2-Q376Q splicing muation: functional characterization, molecular correction and therapeutic implication. 109
Cardiac potassium channel dysfunction in sudden infant death syndrome. 109
QT lungo, sindrome del 108
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation 108
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene 108
Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model 107
KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome. 106
A comprehensive electrocardiographic, molecular, and echocardiographic study of Brugada syndrome: validation of the 2013 diagnostic criteria. 106
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 104
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1 104
From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2 103
Prevalence of the congenital long-QT syndrome. 102
Brugada and Long QT Syndrome are two different diseases: True or False? 102
The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2 102
The ICD for the long QT syndrome: which indications, complications, and results? 100
Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. 100
KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. 100
An International Multi-Center Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. 100
Can a message from the dead save lives? 99
A Refined Multiscale Self-Entropy Approach for the Assessment of Cardiac Control Complexity: Application to Long QT Syndrome Type 1 Patients 99
Response to Letters Regarding Article, "Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation" 98
Genotype-Phenotype Correlation in Induced Pluripotent Stem Cell (iPSC) Derived Cardiomyocytes Carrying Calmodulin Mutations 98
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation 98
Individual autonomic profile contributes to the risk for life-threatening arrhythmias among KCNQ1-A341V mutation carriers 97
Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients. 97
Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. 96
NOS1AP Is a Genetic Modifier of the Long-QT Syndrome 95
Arrhythmogenic calmodulin mutations disrupt intracellular cardiomyocyte Ca2+ regulation by distinct mechanisms. 95
Congenital long QT and short QT syndromes 95
Autonomic control of heart rate and QT interval variability influences arrhythmic risk in long QT syndrome type 1 95
Idiopathic Ventricular Fibrillation. 94
Risk factors for primary ventricular fibrillation during a first myocardial infarction: Clinical findings from PREDESTINATION (PRimary vEntricular fibrillation and suDden dEath during firST myocardIal iNfArcTION) 94
Generation of two human induced pluripotent stem cell (hiPSC) lines from a long QT syndrome South African founder population 93
Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. 92
Filtering approach based on empirical mode decomposition improves the assessment of short scale complexity in long QT syndrome type 1 population 92
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi006-A from a patient affected by an autosomal recessive form of long QT syndrome type 1 92
Torsades de Pointes following Acute Myocardial Infarction: Evidence for a Deadly Link with a Common Genetic Variant. 91
Condizioni cliniche associate ad anomalie dell'intervallo QT: Implicazioni cliniche [Clinical conditions associated with abnormal QT interval: clinical implications]. 90
Clinical management of catecholaminergic polymorphic ventricular tachycardia the role of left cardiac sympathetic denervation 89
Functional characterization and molecular correction of the LQT2 KCNH2-Q376 splicing mutation. Therapeutic implications? 88
Gene symbol: KCNH2 87
QTc behavior during exercise and genetic testing for the long-QT syndrome. 86
Clinical implications for patients with Long QT Syndrome who experience a cardiac event during infancy 86
Time, frequency and information domain analysis of heart period and QT variability in asymptomatic long QT syndrome type 2 patients. 86
Calmodulin mutations associated with recurrent cardiac arrest in infants. 86
Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. 86
Novel calmodulin mutations associated with congenital arrhythmia susceptibility. 85
Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical Features 85
Gene symbol: SCN5A 84
Two cases of sudden unexpected death in epilepsy in a GEFS+ family with an SCN1A mutation. 84
The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. 84
Symbolic analysis of heart period and QT interval variabilities in LQT1 patients 83
Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study. 83
High efficacy of beta-blockers in Long QT Syndrome type 1: contribution of non-compliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”. 83
MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes 83
Mutation-specific risk in two genetic forms of type 3 long QT syndrome. 82
Vagal reflexes following an exercise stress test: a simple clinical tool for gene-specific risk stratification in the long QT syndrome. 82
Ion channel diseases in children: manifestations and management. 82
Gene symbol: KCNH2 82
The Long QT Syndrome 81
Refined multiscale entropy analysis of heart period and QT interval variabilities in long QT syndrome type-1 patients2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 81
Identification of Cadherin 2 (CDH2) Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy. 81
The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. 79
Drug-induced long QT syndrome and exome sequencing: Chinese shadows link past and future. 79
Author Correction: Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility (Nature Genetics, (2022), 54, 3, (232-239), 10.1038/s41588-021-01007-6) 78
Gene symbol: KCNH2. 76
Gene symbol: KCNH2. 76
Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel. 76
Gene expression and arrhythmic risk. 76
Response by Crotti et al to Letter Regarding Article, "Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3' Untranslated Region of KCNQ1?" 76
Gene symbol: KCNQ1. 76
Totale 10.282
Categoria #
all - tutte 53.566
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.566


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021200 0 0 0 0 0 0 0 0 0 99 88 13
2021/2022577 13 5 33 7 13 18 7 43 34 6 90 308
2022/20232.247 232 152 27 246 194 221 2 108 907 6 124 28
2023/2024820 92 136 22 53 73 196 23 77 5 30 65 48
2024/20252.079 45 178 62 51 46 116 103 174 526 74 220 484
2025/20264.325 376 391 519 429 622 202 878 225 426 257 0 0
Totale 13.511